SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.

Original reporting
Published Nov 17, 2026, 2:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint — source image
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

The trial’s OS primary endpoint success and the company’s stated intent to pursue an accelerated filing pathway for a first-half 2027 BLA are the core catalysts for near-term repricing and positioning.

02

Market read

Traders can act on a fresh pivotal clinical readout (OS) and a concrete regulatory filing timeline plan, driving immediate momentum and options/volatility dynamics.

03

What to watch

Key next risks are FDA feedback on the accelerated pathway, BLA dossier completeness, and whether confirmatory evidence requirements could extend timelines or dilute the accelerated benefit.

Relevance 9/10Novelty 9/10Timing: premarket today, after-hours repricing likely ongoing

Background

REGAL is a Phase 3 maintenance monotherapy study in AML patients in second or later complete remission (or CRp2+) who are ineligible for or unable to undergo allogeneic stem cell transplantation.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

SELLAS shares surge after Phase 3 REGAL trial met its overall survival primary endpoint for Galinpepimut-S, cutting death risk by 41% vs BAT.

Expected impact

Likely further upside pressure as traders price in accelerated BLA timing and higher odds of regulatory acceptance, with volatility elevated given trial-to-approval uncertainty.

Evidence & confidence

The article reports a primary endpoint win with OS medians and a stated plan to pursue an accelerated filing pathway, which are direct, decision-relevant catalysts for biotech valuation.

Market effects

Reinforces appetite for immuno-oncology vaccine platforms and can lift sentiment for small-cap oncology biotech trial-readouts.

Primarily US small-cap biotech flow impact; limited direct spillover beyond healthcare growth factors.

Modest global read-through for clinical-trial success expectations in AML maintenance immunotherapy.

Counterpoint

A Phase 3 OS win may already be partially anticipated by the market, and the stock’s magnitude of move can invite profit-taking before FDA interaction details are known.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Sponsor of the REGAL Phase 3 trial for Galinpepimut-S (GPS) in AML maintenance immunotherapy.

  • Galinpepimut-S (GPS)

    Immunotherapeutic cancer vaccine evaluated as maintenance monotherapy in REGAL.

  • FDA

    Regulatory agency SELLAS plans to meet with to discuss an accelerated filing pathway and BLA submission timing.

Related articles

$SLSHighAI 9/10

Why is Sellas Life Sciences stock surging today?

Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

$SLSHighAI 9/10

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.